Bronchoscopy Study for Severe Asthma
Primary Purpose
Severe Persistent Asthma
Status
Withdrawn
Phase
Locations
United States
Study Type
Observational
Intervention
Bronchoscopy
Sponsored by
About this trial
This is an observational trial for Severe Persistent Asthma
Eligibility Criteria
Inclusion Criteria:
Asthma Subject Inclusion Criteria
- Subject is an adult male or female between 18 and 65 years of age inclusive.
- Subject must have a pre-history of a physician's diagnosis of severe asthma (according to GINA classification) with some reversible airway obstruction (shown by peak flow or FEV1 in the last 12 months with a change of 12% in the absolute FEV1 measurement) and an exclusion of other significant pulmonary diseases (i.e., cystic fibrosis, tuberculosis, Interstitial Lung Disease and bronchopulmonary dysplasia)
- Subject has a positive methacholine test (PC20 < 16). This test sometimes cannot be performed in severe asthmatics because of low baseline FEV1 (< FEV1 50%). SABA reversibility of FEV1 is sufficient to define asthma in absence of MCh PC20.
- Subject's asthma has been stable for the past 30 days.
- The subject has been a non-smoker for the past year and should have less than a 10 pack year history.
- The subject must be capable of and willing to provide written informed consent
- The subject is able to understand and comply with protocol requirements and timetables, instructions and protocol-stated restrictions.
Healthy Subject Inclusion Criteria
- Subject is an adult male or female between 18 and 65 years of age inclusive. (Subjects will be age and gender matched) With age matching, we will enroll in a manner that age and gender will be matched 1:1 in the following cohorts: age 21-30, 31-40, 41-50, 51-60, 61-65.
- Subject must have an exclusion of asthma or other significant pulmonary diseases (i.e., cystic fibrosis, tuberculosis, Interstitial Lung Disease and bronchopulmonary dysplasia)
- The subject has been a non-smoker for the past year and should have less than a 10 pack year history.
- The subject has a negative methacholine test (PC20 > 16) and does not use inhaled steroids and/or SABA.
- The subject must be capable of and willing to provide written informed consent
The subject is able to understand and comply with protocol requirements and timetables, instructions and protocol-stated restrictions.
-
Exclusion Criteria:
- As a result of the medical interview, physical examination or screening investigations, the physician responsible considers the volunteer unfit for the study.
- The subject has received an investigational drug or participated in any other research trial within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer), prior to the current study.
- No oral steroids within the last 3 months.
- No current anticoagulant and/or antiplatelet therapy.
- The subject has a history of alcohol or drug abuse within the last 5 years.
- The subject has history of hepatitis B, hepatitis C, or HIV virus.
- The subject has a history of chemotherapy or radiotherapy within the last 2 years.
- The subject has a history of diabetes.
- The subject is pregnant or lactating.
Sites / Locations
- Airways Biology Initiative at the University of Pennsylvania
Arms of the Study
Arm 1
Arm 2
Arm Type
Arm Label
Severe Asthmatics
Healthy non-smokers
Arm Description
Subjects with a pre-existing physician diagnosis of asthma with reversible airflow obstruction of at least 12%.
Subjects will be never smokers or former smokers for the past year and less than 10 pack years lifetime with no history of asthma or any other lung disease.
Outcomes
Primary Outcome Measures
To obtain bronchial brushings and bronchial alveolar lavage fluid from 10 subjects with severe asthma (GINA criteria in The Global Initiative for Asthma, http://www.ginasthma.org ) and from 10 matched normal healthy subjects.
Secondary Outcome Measures
Full Information
NCT ID
NCT01745809
First Posted
December 6, 2012
Last Updated
May 28, 2015
Sponsor
University of Pennsylvania
Collaborators
Centocor, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01745809
Brief Title
Bronchoscopy Study for Severe Asthma
Official Title
An Exploratory Study to Obtain Functional and Transcriptional/Translational Profiling of Cells From Bronchial Lavages and Brushings in Severe Asthmatics and Healthy Control Subjects
Study Type
Observational
2. Study Status
Record Verification Date
October 2011
Overall Recruitment Status
Withdrawn
Why Stopped
Contractual issues
Study Start Date
January 2013 (undefined)
Primary Completion Date
December 2014 (Anticipated)
Study Completion Date
December 2014 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Pennsylvania
Collaborators
Centocor, Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this research study is to collect lung tissue and fluid from two groups of people: those who have severe asthma, and those who do not. These samples will then be tested in a laboratory to identify differences in the lung tissue cells and fluids that may exist between these two groups of people.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Severe Persistent Asthma
7. Study Design
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Severe Asthmatics
Arm Description
Subjects with a pre-existing physician diagnosis of asthma with reversible airflow obstruction of at least 12%.
Arm Title
Healthy non-smokers
Arm Description
Subjects will be never smokers or former smokers for the past year and less than 10 pack years lifetime with no history of asthma or any other lung disease.
Intervention Type
Procedure
Intervention Name(s)
Bronchoscopy
Other Intervention Name(s)
Fiberoptic Bronchoscopy, Bronchoalveolar Lavage
Intervention Description
Subjects will have a screening visit and, if they qualify to take part in the study, they will undergo a single bronchoscopy procedure. During the bronchoscopy, bronchoalveolar lavage (BAL) and bronchial brushings will be performed on each subject.
Primary Outcome Measure Information:
Title
To obtain bronchial brushings and bronchial alveolar lavage fluid from 10 subjects with severe asthma (GINA criteria in The Global Initiative for Asthma, http://www.ginasthma.org ) and from 10 matched normal healthy subjects.
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Asthma Subject Inclusion Criteria
Subject is an adult male or female between 18 and 65 years of age inclusive.
Subject must have a pre-history of a physician's diagnosis of severe asthma (according to GINA classification) with some reversible airway obstruction (shown by peak flow or FEV1 in the last 12 months with a change of 12% in the absolute FEV1 measurement) and an exclusion of other significant pulmonary diseases (i.e., cystic fibrosis, tuberculosis, Interstitial Lung Disease and bronchopulmonary dysplasia)
Subject has a positive methacholine test (PC20 < 16). This test sometimes cannot be performed in severe asthmatics because of low baseline FEV1 (< FEV1 50%). SABA reversibility of FEV1 is sufficient to define asthma in absence of MCh PC20.
Subject's asthma has been stable for the past 30 days.
The subject has been a non-smoker for the past year and should have less than a 10 pack year history.
The subject must be capable of and willing to provide written informed consent
The subject is able to understand and comply with protocol requirements and timetables, instructions and protocol-stated restrictions.
Healthy Subject Inclusion Criteria
Subject is an adult male or female between 18 and 65 years of age inclusive. (Subjects will be age and gender matched) With age matching, we will enroll in a manner that age and gender will be matched 1:1 in the following cohorts: age 21-30, 31-40, 41-50, 51-60, 61-65.
Subject must have an exclusion of asthma or other significant pulmonary diseases (i.e., cystic fibrosis, tuberculosis, Interstitial Lung Disease and bronchopulmonary dysplasia)
The subject has been a non-smoker for the past year and should have less than a 10 pack year history.
The subject has a negative methacholine test (PC20 > 16) and does not use inhaled steroids and/or SABA.
The subject must be capable of and willing to provide written informed consent
The subject is able to understand and comply with protocol requirements and timetables, instructions and protocol-stated restrictions.
-
Exclusion Criteria:
As a result of the medical interview, physical examination or screening investigations, the physician responsible considers the volunteer unfit for the study.
The subject has received an investigational drug or participated in any other research trial within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer), prior to the current study.
No oral steroids within the last 3 months.
No current anticoagulant and/or antiplatelet therapy.
The subject has a history of alcohol or drug abuse within the last 5 years.
The subject has history of hepatitis B, hepatitis C, or HIV virus.
The subject has a history of chemotherapy or radiotherapy within the last 2 years.
The subject has a history of diabetes.
The subject is pregnant or lactating.
Study Population Description
10 severe asthma subjects matched with 10 healthy control subjects
Sampling Method
Non-Probability Sample
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Reynold Panettieri, MD
Organizational Affiliation
University of Pennsylvania
Official's Role
Principal Investigator
Facility Information:
Facility Name
Airways Biology Initiative at the University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Bronchoscopy Study for Severe Asthma
We'll reach out to this number within 24 hrs